Search Results for "Infection"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Infection. Results 281 to 290 of 842 total matches.

A Once-Daily Combination Tablet (Atripla) for HIV

   
The Medical Letter on Drugs and Therapeutics • Sep 25, 2006  (Issue 1244)
) is the first oncedaily, single-tablet combination of 3 antiretroviral drugs for treatment of HIV infection ...
Atripla (Gilead/Bristol-Myers Squibb) is the first once daily, single-tablet combination of 3 antiretroviral drugs for treatment of HIV infection. Each tablet contains 600 mg of the non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz (Sustiva), 200 mg of the nucleoside reverse transcriptase inhibitor (NRTI) emtricitabine (Emtriva), and 300 mg of the nucleotide reverse transcriptase inhibitor (NRTI) tenofovir DF (Viread). These drugs have been recommended for use together, if resistance testing confirms susceptibility, as an initial regimen of choice for treatment-na∩ve...
Med Lett Drugs Ther. 2006 Sep 25;48(1244):78-9 |  Show IntroductionHide Introduction

Canagliflozin (Invokana) for Type 2 Diabetes

   
The Medical Letter on Drugs and Therapeutics • May 13, 2013  (Issue 1416)
Weight loss, low risk of hypo- Genital mycotic infections, urinary 263.00 glycemia tract infection ...
Canagliflozin (kan" a gli floe' zin; Invokana – Janssen), a sodium-glucose co-transporter 2 (SGLT2) inhibitor, has been approved by the FDA for oral treatment of type 2 diabetes.
Med Lett Drugs Ther. 2013 May 13;55(1416):37-9 |  Show IntroductionHide Introduction

Drugs for Pneumonia

   
Treatment Guidelines from The Medical Letter • Sep 01, 2003  (Issue 13)
on the most likely pathogens causing the infection and local antimicrobial resistance patterns. Factors ...
The choice of drugs for treatment of pneumonia depends on the most likely pathogens causing the infection and local antimicrobial resistance patterns. Factors such as severity of illness, presence of co-morbid conditions and whether the infection is community or hospital-acquired also need to be considered.
Treat Guidel Med Lett. 2003 Sep;1(13):83-8 |  Show IntroductionHide Introduction

Lefamulin (Xenleta) for Community-Acquired Bacterial Pneumonia

   
The Medical Letter on Drugs and Therapeutics • Sep 23, 2019  (Issue 1581)
are limited. Lefamulin is also active in vitro against pathogens that cause sexually transmitted infections ...
Lefamulin (Xenleta – Nabriva), a semisynthetic pleuromutilin antibiotic, has been approved by the FDA for IV and oral treatment of community-acquired bacterial pneumonia (CABP) in adults. It is the first systemic pleuromutilin antibiotic to be approved in the US; retapamulin (Altabax), a 1% topical ointment for treatment of impetigo, was approved in 2007.
Med Lett Drugs Ther. 2019 Sep 23;61(1581):145-8 |  Show IntroductionHide Introduction

Booster Doses of COVID-19 Vaccines

   
The Medical Letter on Drugs and Therapeutics • Nov 29, 2021  (Issue 1638)
likely to be infected with SARS-CoV-2 than those who were not vaccinated, but the relative risk ...
The FDA has expanded the Emergency Use Authorizations (EUAs) for the mRNA-based COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) and the adenovirus-based vaccine manufactured by Johnson & Johnson/Janssen to include administration of a booster dose in select populations after primary immunization with either the same COVID-19 vaccine or a different one.
Med Lett Drugs Ther. 2021 Nov 29;63(1638):186-8 |  Show IntroductionHide Introduction

In Brief: Recommendation for Earlier Antibiotic Prophylaxis for Cesarean Delivery

   
The Medical Letter on Drugs and Therapeutics • Oct 04, 2010  (Issue 1348)
of endometritis and wound infection with preoperative antibiotic administration compared to administration post ...
The American Congress of Obstetricians and Gynecologists (ACOG) has announced a new recommendation for antibiotic prophylaxis during cesarean delivery.1 Currently most women receive a single dose of prophylactic antibiotics after the umbilical cord has been clamped to prevent antibiotics from crossing over to the newborn. The new recommendation is for women giving birth by cesarean section to routinely receive antibiotics within one hour before the start of surgery. In the case of an emergency cesarean delivery, prophylaxis should be started as soon as possible.Recent studies have found a...
Med Lett Drugs Ther. 2010 Oct 4;52(1348):80 |  Show IntroductionHide Introduction

Mumps Outbreak

   
The Medical Letter on Drugs and Therapeutics • Mar 17, 2014  (Issue 1438)
in older people could be due to a lower level of exposure or superior immunity from natural infection ...
An outbreak of mumps has occurred among students at Fordham University in New York. All of those who developed mumps had been vaccinated against the disease.
Med Lett Drugs Ther. 2014 Mar 17;56(1438):21 |  Show IntroductionHide Introduction

In Brief: A New Formulation of Posaconazole (Noxafil)

   
The Medical Letter on Drugs and Therapeutics • Feb 02, 2015  (Issue 1461)
drug posaconazole (Noxafil - Merck) for prophylaxis of Aspergillus and Candida infections in adults ...
The FDA has approved an IV formulation of the antifungal drug posaconazole (Noxafil - Merck) for prophylaxis of Aspergillus and Candida infections in adults at high risk for these infections, such as those with prolonged neutropenia. Posaconazole is also available as delayed-release tablets and an oral suspension.With activity against Aspergillus and Candida, posaconazole has an antifungal spectrum similar to that of voriconazole (Vfend, and generics), but unlike voriconazole it is also active against many species of Mucorales (formerly called Zygomycetes), such as Mucor and Rhizopus....
Med Lett Drugs Ther. 2015 Feb 2;57(1461):20 |  Show IntroductionHide Introduction

Atovaquone for Pneumocystis Carinii Pneumonia

   
The Medical Letter on Drugs and Therapeutics • Apr 02, 1993  (Issue 893)
opportunistic infection and frequent cause of death in patients with AIDS. STANDARD THERAPY — Trimethoprim ...
Atovaquone (Mepron - Burroughs Wellcome), a hydroxynaphthoquinone, was recently approved by the US Food and Drug Administration (FDA) for oral treatment of mild to moderate Pneumocystis carinii pneumonia (PCP) in patients who cannot tolerate trimethoprim-sulfamethoxazole (Septra, Bactrim, and others). PCP is a common opportunistic infection and frequent cause of death in patients with AIDS.
Med Lett Drugs Ther. 1993 Apr 2;35(893):28-9 |  Show IntroductionHide Introduction

Aerosolized Deoxyribonuclease for Cystic Fibrosis

   
The Medical Letter on Drugs and Therapeutics • Apr 15, 1994  (Issue 920)
in the mucus-obstructed airways of patients with cystic fibrosis leads to recurrent pulmonary infections ...
Recombinant human deoxyribonuclease I (rhDNase; dornase alfa; Pulmozyme - Genentech), an enzyme that hydrolyzes extracellular DNA, is now available as a purified solution to decrease the viscosity of sputum in patients with cystic fibrosis. It requires a nebulizer to produce an aerosol mist for inhalation.
Med Lett Drugs Ther. 1994 Apr 15;36(920):34-5 |  Show IntroductionHide Introduction